Verge HealthTech Fund

What Verge HealthTech Fund does

Verge HealthTech Fund is a Singapore-based early-stage venture capital firm founded in 2018 that invests in health technology startups globally from pre-seed through Series A. The fund operates a thesis-driven approach across six core areas: AI and Data Analytics, Next-Generation Diagnostics, Breakthrough Smart Devices, Digital Health Platforms, Digital Therapeutics, and Healthcare SaaS. Verge has assembled a portfolio of 36 companies operating across 49 countries, with 22 of those in low- and middle-income markets, and claims impact on more than 34 million lives.

The firm follows standard VC economics: management fees on committed/assets under management plus carried interest on fund profits. Fund I reached a $7.6 million first close in 2021, while Fund II has secured institutional commitments from J&J Impact Ventures (December 2023), MSD Impact Venture Fund (April 2025), and GHIC via the Catalytic Health Investment Platform with Germany's KfW (July 2025). Typical investment tickets range from $500K to $1.5M per portfolio company. Verge's portfolio spans well-known names including Pathway (acquired by Doximity), Health2Sync (OTC-listed in Taiwan, 1.7M+ users), CuboAi (Series B, 250,000+ units sold), RetiSpec (CB Insights Digital Health 50), and reach52 (3.8M people reached across Asia/Africa).

Verge's core differentiator is its operator-investor model: a lean 10-person core team of clinicians, scientists, and former healthtech founders (100+ years of combined experience) provides hands-on portfolio support across FDA/CE regulatory navigation, clinical trial structuring, hospital partner introductions, and cross-border commercialization bridging Asian, European, and US markets. Deal sourcing runs through direct founder relationships, a 13+ member global venture partner network, conference presence (e.g., Arab Health), and an open website submission portal that reviews every pitch.

Name

Verge HealthTech Fund

Legal name

Verge HealthTech Fund

Website

https://verge.fund

Company type

Private

Founded year

2018

Operating status

Operating

Short description

Singapore-based early-stage healthtech venture capital firm (founded 2018) investing pre-seed to Series A globally. Manages Fund I ($7.6M first close) and Fund II, with 36 portfolio companies across 49 countries and a thesis-driven focus on AI, diagnostics, smart devices, and digital therapeutics.

Ownership category

akta.pro rank

Product category

Healthtech Venture Capital

NAICS

Finance and Insurance (52)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

akta.pro secondary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

Keywords

• Venture capital fund
• Healthtech investments
• Early-stage startups
• Portfolio management
• Health technology investing

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Fund Management Fees: Verge HealthTech Fund generates revenue through traditional VC fund management fees, typically charged as a percentage of assets under management (AUM). The fund manages multiple vehicles including a pilot fund and Fund II.
2. Carried Interest: VC fund structure with carried interest (typically 20%) on profits above the hurdle rate, aligning investor and fund manager interests.
3. Portfolio Company Success: Returns from successful portfolio companies through exits via IPO, acquisition, or secondary transactions. Examples include Pathway (acquired by Doximity), Health2Sync (OTC listed in Taiwan), and various portfolio companies raising follow-on rounds.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Verge HealthTech Fund is an early-stage venture capital fund that invests in healthtech startups from pre-seed to Series A, with typical ticket sizes of $500K to $1.5M. The fund provides portfolio companies with clinical, regulatory, and commercial expertise across six investment theses (AI and Data Analytics, Next Gen Diagnostics, Breakthrough Smart Devices, Digital Health Platforms, Digital Therapeutics, and Healthcare SaaS), managing a portfolio of 36 companies across 49 countries.

Product overview

Verge HealthTech Fund operates as an early-stage venture capital fund focused on health technology investments globally, rather than as a product company. The fund's investment scope encompasses six primary technology areas: AI and Data Analytics solutions that extract actionable insights from healthcare data; Next Gen Diagnostics incorporating cutting-edge detection technologies and biomarkers; Breakthrough Smart Devices including innovative wearables and portable devices; Digital Health Platforms facilitating telemedicine, remote patient monitoring, and chronic disease management; Digital Therapeutics used as therapeutic interventions for specific health conditions; and Healthcare SaaS platforms for healthcare operations. The fund has built a portfolio of 36 healthtech companies at various stages from Pre-Seed to Series B, with geographic reach across 49 countries and 22 LMIC markets. The portfolio companies collectively offer diverse solutions spanning digital pharmacy, AI-powered clinical decision support, digital therapeutics, diagnostic devices, mental health platforms, and various health technology innovations.

Differentiator

Problem solved

Functional benefit

Products and services

• Verge HealthTech Fund I Verge's debut venture capital fund providing early-stage healthtech equity investments from pre-seed to Series A, targeting visionary founders developing technology-centric health solutions. The fund reached its first close at $7.6M in 2021 and built the foundation portfolio that established Verge's track record.
• Verge HealthTech Fund II Verge's second healthtech venture capital fund building on Fund I momentum, attracting major institutional impact investors including J&J Impact Ventures, MSD Impact Venture Fund, and GHIC. Fund II invests in high-potential healthtech companies developing remote endoscopy, AI-powered clinical decision support, and digital biomarkers for neurological disorders.

Quantifiable outcome

• 34+ million lives impacted across global portfolio
• +2 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability14 records

Feature6 records

Partnerships

Four partnerships are on record, tiered key investor network member, strategic partner, founding partner and partner.

• Eir Accelerator / Women's Health Hub Finlandkey investor network memberStrategic or Co-development Partner · 4 June 2026Verge HealthTech Fund is a key member of the international investor network backing the newly launched Eir Accelerator, a dedicated women's health startup program established by the Women's Health Hub Finland. The six-month acceleration program supports early-stage femtech and women's health startups from the Nordics and wider Europe by helping them generate clinical evidence, navigate European and U.S. regulations, and build partnerships with major pharma companies including Bayer, Organon, and Orion.
• VAMBRA (Vietnam Association of Medical Biological Research and Application)strategic partnerStrategic or Co-development Partner · 27 March 2026VAMBRA signed an MOU with Verge HealthTech Fund to drive MedTech and digital health innovation in Vietnam. The partnership focuses on technology assessment, pilot implementations of emerging health-tech solutions in local hospitals, and supporting market entry and co-investments.
• Impact Investment Initiative (Triple I) for Global Healthfounding partnerStrategic or Co-development Partner · 4 October 2024Verge HealthTech Fund is a founding partner-organization of the Impact Investment Initiative (Triple I) for Global Health. Endorsed by the G7, Triple I aims to raise awareness and share best practices on how to leverage impact investing to contribute to global health under Sustainable Development Goal 3 of the UN.
• #i2.JPpartnerStrategic or Co-development Partner · 7 February 2024Verge HealthTech Fund joined #i2.JP, an open innovation network dedicated to realizing patient-centricity in Japan. i2.JP is a community of healthcare professionals, local governments, academia, and private companies to help Japan address complex healthcare challenges.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Andreessen Horowitz (a16z Bio/Health Fund): Major US venture firm with dedicated bio/health fund investing from seed to growth in digital health, biotech, and care delivery. Comparable as a high-profile healthtech investor, though significantly larger and broader in mandate than Verge.
• ARCH Venture Partners: Established US venture firm investing in early-stage life sciences, biotech, and healthtech. Comparable in stage focus (pre-seed/seed/early) and healthtech orientation, though ARCH skews toward deep biotech rather than digital health platforms.
• Khosla Ventures: Large US venture firm with a meaningful healthtech and digital health practice spanning seed through growth. Comparable in healthtech seed investing and impact orientation (Vinod Khosla's clean-tech/health mission), though far larger AUM.

Direct peers

• Lux Capital: US venture firm investing in frontier tech and healthtech at seed and Series A. Directly comparable thesis overlap on science-driven, technically complex healthtech bets (AI, diagnostics, devices) at similar early stages.
• Section32: US-based venture fund investing in early-stage healthcare and tech-enabled health companies. Closely comparable as a specialist healthtech seed/Series A investor focused on AI, digital health, and novel care models.
• HealthXCapital: Singapore- and India-based early-stage VC dedicated exclusively to digital health and healthtech in Asia. Direct peer given overlap in geography (Singapore HQ, emerging Asia focus), stage (pre-seed/seed), and digital health thesis.
• Wavemaker Partners: APAC-focused early-stage venture firm with a dedicated healthtech practice (Wavemaker 360 Health). Comparable in Singapore/Asia presence, early-stage healthtech thesis, and hands-on operating support model.

Emerging players

• LeapFrog Investments: Emerging-market impact investor with healthcare and financial services focus across Africa and Asia. Comparable on impact mandate, LMIC focus, and healthcare access thesis, though LeapFrog deploys larger tickets and growth-stage capital.
• Acumen: Global impact investor (acumen.org) backing early-stage companies addressing poverty including health. Comparable on impact/ESG mandate and emerging-market health focus, with longer holding periods and development-finance LP base similar to Verge's.
• Novastar Ventures: Africa-focused impact venture firm investing in early-stage consumer and health businesses serving low-income populations. Comparable on impact-LP base, emerging-market health focus, and stage (seed/Series A), though Africa-concentrated rather than global.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/verge-healthtech-fund

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verge HealthTech Fund